Slide 1: Strategic Reset and HY26 Results
25 February 2026 Steven Lydeamore Chief Executive Officer Strategic Reset and HY26 Results NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: The Immuron Investment Thesis
3 The Immuron Investment Thesis Immuron is a commercial - stage biopharmaceutical company (NASDAQ: IMRN) using a proprietary "Hyper - Immune" platform to create naturally - derived, oral antibody therapies for gut health and infectious diseases. The Competitive “Moat” • Consistent Revenue Growth : I
Slide 4: The Technology: Hyper-Immune Protection
4 The Technology: "Hyper - Immune" Protection • Immuron’s core strength lies in its ability to program cows to produce high levels of specific polyclonal antibodies ( immunoglobulins ) through vaccination. • Orally Active: Unlike many biologics that require injection, Immuron’s bovine antibodies are
Slide 5: Risk Management & Supply Chain
5 Risk Management & Supply Chain Immuron has de - risked its supply chain through: • Safe Sourcing: All colostrum is sourced from Australia or New Zealand — Category 1 countries with negligible risk of BSE (Mad Cow Disease). • Scalable Partnerships: Supply agreements with dairy farms in Gippsland an
Slide 6: Growth Catalysts & Competitive Edge
6 Growth Catalysts & Competitive Edge • Broad Platform Utility: This isn't a one - trick pony. The technology can be applied to a range of infectious diseases, creating a deep pipeline of potential drug candidates. • High Barrier to Entry: The company’s proprietary vaccination protocols and the "hyp
Slide 7: 1. Financial & Operational Highlights
1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 8: HY26 Financial Summary
8 HY26 Financial Summary Global Sales Revenue $4.2m Up 5% Australian Sales Revenue $3.3m Up 13% North American Sales Revenue $0.9m Down 1 18% USA Up 17% Gross Profit Margin 63% EBITDX (ex - R&D) 2 $(1.1)m Up $0.1m Up $0.7m on H2 FY25 4 Cash $10.0m Up $7.2m 3 on 30 Jun 25 ≈ 23.5 months cash (calculat
Slide 9: Continued strong sales growth
9 Continued strong sales growth Global + HY2026 AUD$4.2 million up 5% on prior year Australia + HY2026 AUD$3.3 million up 13% on prior year North America + HY2026 AUD$0.9 million down 18% on prior year + USA HY2026 AUD$0.9 million up 17% on prior year + Post HY, secured distribution with Jean Coutu
Slide 10: Commercial – Operational Highlights and Outlook
10 Commercial – Operational Highlights 2H FY24 1H FY25 2H FY25 1H FY26 and Outlook 1 Refer Travelan ® / Protectyn® • $4.18m global sales • $3.27m Australia • $0.91m North America • $3.29m global sales • $2.36m Australia • $0.93m North America • $3.99m global sales • $2.89m Australia • $1.11m North A
Slide 11: 2. Clinical Development Program
2. CLINICAL DEVELOPMENT PROGRAM
Slide 12: Revenue generating with a strong clinical development pipeline
12 Revenue generating with a strong clinical development pipeline 27 February 2026 29 August 2025 Indication • Immuron has advanced discussions with AFRIMS to conduct testing of Travelan® against EAEC and EPEC strains of E.coli • Immuron will seek partners to advance clinical development of Travelan
Slide 13: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: